Wall Street analysts forecast that Urogen Pharma Ltd (NASDAQ:URGN) will announce earnings per share of ($1.08) for the current quarter, according to Zacks. Zero analysts have provided estimates for Urogen Pharma’s earnings. The highest EPS estimate is ($1.02) and the lowest is ($1.14). Urogen Pharma posted earnings per share of ($0.02) in the same quarter last year, which would suggest a negative year-over-year growth rate of 5,300%. The firm is expected to announce its next earnings results on Tuesday, November 13th.

On average, analysts expect that Urogen Pharma will report full-year earnings of ($4.12) per share for the current financial year, with EPS estimates ranging from ($4.32) to ($3.89). For the next year, analysts anticipate that the business will report earnings of ($4.93) per share, with EPS estimates ranging from ($6.71) to ($3.47). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Urogen Pharma.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.25). The business had revenue of $0.36 million for the quarter. Urogen Pharma had a negative net margin of 470.54% and a negative return on equity of 44.24%.

Several research firms recently weighed in on URGN. Stifel Nicolaus began coverage on shares of Urogen Pharma in a report on Thursday, September 13th. They set a “buy” rating and a $70.00 price target on the stock. ValuEngine upgraded shares of Urogen Pharma from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Cowen restated a “buy” rating on shares of Urogen Pharma in a report on Tuesday, August 14th. Finally, Oppenheimer set a $75.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a report on Tuesday, August 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Urogen Pharma has a consensus rating of “Buy” and a consensus target price of $59.60.

Institutional investors have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Urogen Pharma during the second quarter worth about $129,000. Quantbot Technologies LP purchased a new position in Urogen Pharma during the first quarter worth about $174,000. UBS Group AG boosted its holdings in Urogen Pharma by 31.5% during the first quarter. UBS Group AG now owns 3,611 shares of the company’s stock worth $180,000 after purchasing an additional 865 shares during the last quarter. DAFNA Capital Management LLC purchased a new position in Urogen Pharma during the first quarter worth about $224,000. Finally, Jane Street Group LLC purchased a new position in Urogen Pharma during the second quarter worth about $227,000. Institutional investors and hedge funds own 71.11% of the company’s stock.

Shares of NASDAQ URGN traded down $0.12 during mid-day trading on Tuesday, reaching $48.90. 30,500 shares of the company’s stock traded hands, compared to its average volume of 113,268. The stock has a market capitalization of $681.11 million, a P/E ratio of -22.85 and a beta of 2.01. Urogen Pharma has a 1-year low of $25.56 and a 1-year high of $69.57.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.